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Abstract: Ala-Ala-Pro-Val (AAPV) is a bioactive tetrapeptide that inhibits human 
neutrophil elastase (HNE), an enzyme involved in skin chronic inflammatory diseases 
like psoriasis. Caged derivatives of this peptide were prepared by proper N- and C-
terminal derivatisation through a carbamate or ester linkage, respectively, with two 
photoactive moieties, namely 7-methoxycoumarin-2-ylmethyl and pyren-2-ylmethyl 
groups. These groups were chosen to assess the influence of the photosensitive group 
and the type of linkage in the controlled photorelease of the active molecule. The caged 
peptides were irradiated at selected wavelengths of irradiation (254, 300, and 350 nm), 
and the photolytic process was monitored by HPLC-UV. The results established the 
applicability of the tested photoactive groups for the release of AAPV, especially for the 
derivative bearing the carbamate-linked pyrenylmethyl group, which displayed the 
shortest irradiation times for the release at the various wavelengths of irradiation (ca. 4 
min at 254 nm, 8 min at 300 nm and 46 min at 350 nm). 
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Introduction 
The tetrapeptide Ala-Ala-Pro-Val (AAPV) has been evaluated in the treatment of 
psoriasis, a chronic inflammatory disease of the skin, as a competitive inhibitor of 
human neutrophil elastase (HNE). This enzyme relates physiologically to immune 
processes and the extracellular matrix remodelling after tissue injury (Wiedow et al 
1995; Vasconcelos et al. 2011; Caccetta et al. 2006; Namjoshi et al. 2014; Macdonald et 
al. 1998; Hassal et al. 1985). In healthy conditions, the proteolytic activity of this 
enzyme is controlled by endogenous inhibitors; however, in inflammatory processes an 
unbalance occurs between the levels of HNE, which is produced in high levels, and its 
endogenous inhibitors, leading to an abnormal tissue destruction (Namjoshi et al. 2008; 
Benson et al. 2003; Avlonitis et al. 2013).  
Several derivatives of AAPV have been proposed with modifications aiming at 
improving skin absorption and passage through the stratum corneum in order to allow 
efficient transdermal delivery and be able to provide a therapeutic effect with the least 
possible side effects. Reported modifications include preparing peptide conjugates with 
PEG possessing higher lipophilicity (Yingyuad et al. 2014), by coupling to short chain 
lipoaminoacids (Caccetta et al. 2006; Namjoshi et al. 2014; Benson et al. 2003; Toth et 
al. 1995; Rocco et al. 2016; Benson and Namjoshi 2008), and encapsulating the peptide 
in hydrophobic carriers improving its absorption through the stratum corneum (Toth et 
al. 1995; Benson and Namjoshi 2008). For example, improved efficacy of this 
tetrapeptide as an inhibitor of HNE was demonstrated by conjugating the N-terminus 
with one, two or three lipid groups, wherein the inhibitory potency of the lipopeptides in 
relation to the skin HNE increased about ten thousand times compared with the 
unconjugated tetrapeptide (Caccetta et al. 2006; Benson et al. 2003). 
Most peptides do not show ideal features to formulate drugs due to their intrinsic 
physico-chemical and pharmacokinetic profiles and often therapeutic peptides have 
limitations such as low oral bioavailability, short half-life due to rapid degradation by 
proteolytic enzymes and blood plasma, rapid elimination from the systemic circulation 
by hepatic and renal clearance, low capacity to cross physiological barriers due to their 
hydrophilicity, high conformational flexibility which can cause a lack of selectivity for 
the target to interact with different receptors, and immunogenic risks. The strategy for 
chemical optimization of a therapeutic peptide is usually based on structure-activity 
relationship studies in order to improve bioavailability, reduce or eliminate degradation 
and increase selectivity or affinity for the corresponding receptor (Vlieghe et al. 2010). 
Prodrugs are, thus, inactive forms of a drug that, after efficient transfer to the target site, 
suffer proper transformation to release the active drug with control over space and time. 
It is crucial to control the scission of chemical bonds between the active drug and the 
moiety that masks the activity, and among the various triggering stimuli that can be 
used, i.e. enzymes, reducing or oxidising agents, temperature or pH, the use of light 
represents a fast-developing methodology for application in controlled drug delivery 
(Bildstein et al. 2011; Kratz et al. 2008; Jin et al. 2014). 
Photocontrolled triggering and delivery have known an exponential growth in recent 
years, as it allows the cleavage of specific bonds within a structure with the consequent 
removal of the photoactive moiety (linked covalently to the active drug molecule) and 
the on demand/on site release of an active molecule. Among the numerous examples of 
biological phototriggering applications, reports can be found on caged capsaicin 
analogues for the in vitro activation of the capsaicin receptor TRPV1(Carr et al. 2006), 
short oligonucleotide uracil prodrugs for the inhibition of cancer cell proliferation 
(Fujimoto et al. 2014), protein biosynthesis using a caged aminoacyl-tRNA (Akahoshi 
et al. 2014), caged hydrogen sulfide for delivery to live cells (Fukushima et al. 2015), 
photo-uncaging of nitric oxide for targeting to mitochondria (Horinouchi et al. 2011), 
caged agonists for light-activated gene patterning (Link et al. 2004), molecular release 
based on auto-degradable polymer-containing organic–inorganic hybrids (Okada et al. 
2014), photo-control of binding affinity to phosphopeptide-recognizing protein 
(Ebisuno et al. 2014),  and light-switched inhibitors of protein tyrosine phosphatase 
PTP1B (Wagner et al. 2015).
 
In recent years, our research has been focused on the release of bioactive molecules 
mainly from heterocyclic cages, specifically designed for being triggered by light, to act 
as photoremovable protecting groups and phototriggers. Coumarin, benzocoumarin and 
pyrene derivatives, among other moieties, have been designed and applied in the caging 
of amino acids, neurotransmitters, biogenic amines, butyric acid and 5-aminolevulinic 
acid (Fernandes et al. 2007; Fernandes et al. 2008; Soares et al. 2010; Hungerford et al. 
2010; Fonseca et al. 2010; Soares et al. 2012; Piloto et al. 2013; Fernandes et al. 2013; 
Piloto et al. 2015; Soares et al. 2015a; Soares et al. 2015b; Soares et al. 2017). 
Considering our past experience in such phototriggers, and although both photoactive 
moieties used in this manuscript have been previously reported by us, to the best of our 
knowledge the present work is the first account on the application of 7-
methoxycoumarin-2-ylmethyl and pyren-2-ylmethyl groups in the preparation of caged 
tetrapeptide AAPV (a bioactive peptide). The introduction of lipophilic phototriggers 
might also enhance the caged peptide’s lipophilicity and the study of its light-triggered 
uncaging may lead, in future work, to a novel application scope aided by light, for 
example, in topical skin treatment of psoriasis and dermatitis. 
 
Experimental Section 
 
General  
All melting points were measured on a Stuart SMP3 apparatus. TLC analyses were 
carried out on 0.25 mm thick precoated silica plates (Merck Fertigplatten Kieselgel 
60F254) and spots were visualised under UV light. Chromatography on silica gel was 
carried out on Merck Kieselgel (230-240 mesh). Fluorescence spectra were collected 
using a FluoroMax-4 spectrofluorometer (Horiba/Jobin-Yvon). NMR spectra were 
obtained on a Bruker Avance III 400 at an operating frequency of 400 MHz for 
1
H and 
100.6 MHz for 
13
C using the solvent peak as internal reference at 25 
o
C. All chemical 
shifts are given in ppm using δH Me4Si = 0 ppm as reference and J values are given in 
Hz. Assignments were supported by bidimensional heteronuclear correlation 
techniques. Microwave-assisted solid phase peptide synthesis was carried out on a CEM 
Discover SPS equipment. Peptide analysis was carried out with analytical HPLC using 
a Licrospher 100 RP18 (5 μm) column in a JASCO HPLC system composed by a PU-
2080 pump and a UV-2070 detector with ChromNav software. Mass spectrometry 
analyses were performed at the “C.A.C.T.I. - Unidad de Espectrometria de Masas”, at 
University of Vigo, Spain. 4-Chloromethyl-7-methoxycoumarin 1a was synthesised as 
reported elsewhere (Piloto et al. 2006). 1-Chloromethylpyrene 1b was purchased from 
TCI Chemicals, 1-pyrenemethanol 1c from Sigma-Aldrich, Fmoc-Val-OH, Fmoc-Pro-
OH, Fmoc-Ala-OH, N,N′-diisopropylcarbodiimide (DIC), 6-chloro-N-
hydroxybenzotriazole (6-Cl-HOBt) and 2-chlorotrityl chloride resin (degree of 
functionalisation 84%) were purchased from AAPPTec and N,N-diisopropylethylamine 
(DIPEA) was purchased from ACROS Organics and used as received.  
 
MW-assisted solid phase synthesis of Fmoc-Ala-Ala-Pro-Val-OH 2a  
 
Coupling of Fmoc-Val-OH to resin. Fmoc-Val-OH (0.858 g, 2.53
 
mmol, 2 equiv) was 
dissolved in dry DMF (7 mL) and DIPEA was added (878 µL, 5.04 mmol, 4 equiv). The 
mixture was stirred for 10 minutes and then it was added to the previously swollen 2-
chlorotrityl resin (1.51 g, 1.27 mmol) in dry DMF. The suspension was then subjected 
to microwave irradiation for 30 minutes (power = 25 W, temperature = 38 °C). The 
resin was filtered and washed with MeOH (2 × 10 mL), DMF (2 × 10 mL) and MeOH 
(2 × 10 mL) and this washing cycle was repeated 2 times. The filtered resin was dried in 
vacuum. 
 
Removal of Fmoc protecting group. The filtered resin was swollen in DMF for 15 min 
and subjected to an initial deprotection to remove the Fmoc group using a solution of 
20% piperidine in DMF (7 mL/g resin) for 30 seconds, under microwave irradiation 
(power = 28 W, temperature = 75 °C). The resin was washed with DMF (2 × 10 mL), 
MeOH (2 × 10 mL) and DMF (2 × 10 mL). A fresh solution of 20% piperidine in DMF 
was added to the resin and allowed to react for 3 minutes under microwave irradiation 
(power = 28 W, temperature = 75 °C). The resin was washed with DMF (2 × 10 mL) 
and MeOH (2 × 10 mL), and this washing cycle was repeated 3 times. The loading after 
the coupling of the first amino acid was determined to be 0.39 mmol/g, by taking a 
small sample of the resin (10 mg), cleaving the Fmoc group as stated and measuring 
the liberated dibenzofluvene by UV-vis absorption spectroscopy at 290 nm (Chan and 
White 2000). 
 
Coupling of the remaining amino acids. Fmoc-Pro-OH (0.992 g, 2.94 mmol, 5 equiv) 
was dissolved in dry DMF (6 mL/g resin) and DIC (512 µL, 2.94 mmol, 5 equiv) and 6-
Cl-HOBt (0.397 g, 2.94 mmol, 5 equiv) dissolved in dry DMF (2 mL/g) were added. 
The reaction mixture was allowed to stir at room temperature for 15 minutes and then 
was added to the resin, previously swollen in DMF. The suspension was subjected to 
microwave irradiation for 5 min (power = 28 W, temperature = 75 °C). The resin was 
washed with DMF (2 × 10 mL) followed by MeOH (2 × 10 mL) and this washing cycle 
was repeated 3 times. The filtered resin was swollen in dry DMF and the N-terminal 
Fmoc group was removed as described above.  
The same procedure was followed twice for the coupling of Fmoc-Ala-OH, but the final 
N-deprotection was not carried out, in order to keep the Fmoc group at the N-terminal. 
 
Cleavage from the resin. The filtered resin was swollen in dry DMF and a solution of 
AcOH/TFE/DCM (1:1:3) (10 mL) was added. The suspension was stirred for 1 hour at 
room temperature and then the solvent mixture was collected by filtration. The resin 
was washed with DMF (2 × 10 mL) and DCM (2 × 10 mL) and the solvents were 
combined and evaporated to dryness on a rotary evaporator without heating. Cold 
diethyl ether was added and a colourless solid separated, which was filtered. The purity 
of the peptide was checked by analytical HPLC. The peptide Fmoc-Ala-Ala-Pro-Val-
OH 2a was obtained as a colourless solid (0.290 g, 85%). Mp = 94.0-95.2 ºC. 
1
H NMR 
(CDCl3, 400 MHz): δ 0.88-0.91 (6H, m, 2 × -CH3-Val), 1.35-1.39 (6H, m, 2 × CH3 
Ala), 2.02-2.08 (2H, m, H-3 Pro), 2.18-2.38 (3H, m, β-CH Val and H-4 Pro), 3.71-3.76 
(2H, m, H-5 Pro), 4.22 (1H, t, J 7.2 Hz, H-9 Fmoc), 4.37-4.41 (3H, m, α-CH Ala and 
CH2 Fmoc), 4.52-4.55 (1H, m, α-CH Val), 4.69 (1H, d, J 6 Hz, α-CH Pro), 4.83 (1H, t, J 
6.8 Hz, α-CH Ala), 5.57 (1H, d, J 6.8 Hz, NH), 7.31 (2H, t, J 7.6 Hz, H-2 and H-7 
Fmoc), 7.42 (3H, t, J 7.2 and 8.4 Hz, NH, H-3 and H-6 Fmoc), 7.60 (2H, d, J 7.6 Hz, H-
4 and H-5 Fmoc), 7.63 (1H, d, J 6.8 Hz, NH), 7.76 (2H, d, J 7.2 Hz, H-1 and H-8 
Fmoc).
13
C NMR (CDCl3, 100.6 MHz): δ 17.56 (-CH3 Val), 17.99 (CH3 Ala), 18.93 (-
CH3 Val), 19.11 (CH3 Ala), 25.03 (C-4 Pro), 29.68 (C-3 Pro), 31.35 (β-CH Val), 46.64 
(α-CH Ala), 47.11 (C-9 Fmoc), 47.61 (C-5 Pro), 50.31 (α-CH Ala), 57.24 (α-CH Val), 
60.27 (α-CH Pro), 67.11 (CH2 Fmoc), 119.97 (C-1 and C-8 Fmoc), 125.11 (C-4 and C-5 
Fmoc), 127.07 (C-2 and C-7 Fmoc), 127.71 (C-3 and C-6 Fmoc), 141.23 (C-4a and C-
4b Fmoc), 143.75 (C-1a Fmoc), 143.86 (C-8a Fmoc), 155.88 (C=O Fmoc), 170.79 
(C=O Pro), 172.37 (C=O Ala), 172.94 (C=O Ala), 174.42 (C=O Val). HRMS (ESI): 
calcd for C31H39N4O7 [M
+
+H]: 579.28207; found: 579.28174. 
 
Synthesis of H-Ala-Ala-Pro-Val-OH 2b. The Fmoc-protected peptide 2a (0.200 g, 
0.35 mmol) was treated with a solution of 20% piperidine in DMF (3 mL), with stirring 
at room temperature for 3 hours. The mixture was treated with diethyl ether to 
precipitate the resulting peptide 2b (0.112 g, 90%) which was filtered and used 
immediately in the following reactions. 
1
H NMR (CDCl3, 400 MHz): δ 0.94-0.98 (6H, 
m, 2 × -CH3 Val), 1.42 (3H, d, J 7.2 Hz,  CH3 Ala), 1.50 (3H, d, J 7.2 Hz,  CH3 Ala), 
2.00-2.20 (5H, m, β-CH Val, H-3 Pro and H-4 Pro), 3.70-3.75 (2H, m, H-5 Pro), 3.98-
4.00 (1H, m, α-CH Ala), 4.19-4.21 (1H, m, α-CH Val), 4.54-4.56 (1H, m, α-CH Pro), 
4.67-4.69 (1H, m, α-CH Ala), 5.10 (2H, br s, NH2), 8.00 (2H, br s, 2 × NH). 
 
Synthesis of Boc-Ala-Ala-Pro-Val-OH 2c. The peptide H-Ala-Ala-Pro-Val-OH 2b 
(0.100 g, 0.18 mmol) was dissolved in a 1,4-dioxane (3.6 mL), water (1.8 mL) and 
sodium hydroxide 1 M aqueous solution (1.8 mL), with stirring in an ice bath. t-Butyl 
pyrocarbonate (0.044 g, 0.20 mmol, 1.1 equiv) was added and the mixture stirred at 
room temperature for 1 day. The volume was reduced by half in a rotary evaporator 
under reduced pressure and ethyl acetate (2 mL) was added. The mixture was acidified 
by addition of aqueous potassium hydrogen sulphate 1 M solution and extracted with 
ethyl acetate (3 × 5 mL), followed by washing of the organic layer with water (3 × 5 
mL). The organic layer was dried with anhydrous magnesium sulphate and evaporated 
under reduced pressure, resulting an oily off-white solid (0.067 g, 82%). 
1
H NMR 
(CDCl3, 400 MHz): δ 0.84-0.88 (6H, m, 2 × -CH3 Val), 1.38 (3H, d, J 7.2 Hz,  CH3 
Ala), 1.45 (3H, d, J 7.2 Hz,  CH3 Ala), 1.48 (9H, s, C(CH3)3),  1.67-1.71 (2H, m, H-4 
Pro), 1.83-2.05 (2H, m, H-3 Pro), 2.23-2.31 (1H, m, β-CH Val), 3.53-3.61 (2H, m, H-5 
Pro), 4.27 (1H, br s, α-CH Val), 4.43-4.46 (1H, m, α-CH Pro), 4.65-4.67 (1H, m, α-CH 
Ala), 4.74 (1H, q, J 7.2 Hz, α-CH Ala), 5.21 (1H, d, J 7.6 Hz, NH), 7.30 (2H, br s, 2 × 
NH).  
 
Synthesis of H-Ala-Ala-Pro-Val-OMe 2d. The peptide H-Ala-Ala-Pro-Val-OH 2b 
(0.100 g, 0.18 mmol) was added to a previously prepared solution of thionyl chloride 
(14 µL, 0.18 mmol) in methanol (3 mL), in an ice bath. The solution was stirred for 8 
hours at room temperature and the solvent was evaporated under reduced pressure 
without heating, yielding peptide 2d in the form of hydrochloride salt as an off-white 
crystalline solid (0.070 g, quantitative). 
1
H NMR (CDCl3, 400 MHz): δ 0.88-0.91 (6H, 
m, 2 × -CH3 Val), 1.40 (3H, d, J 7.2 Hz,  CH3 Ala), 1.47 (3H, d, J 7.2 Hz,  CH3 
Ala),1.69-1.72 (2H, m, H-4 Pro), 1.82-2.04 (2H, m, H-3 Pro), 2.20-2.30 (1H, m, β-CH 
Val), 3.54-3.63 (2H, m, H-5 Pro), 3.70 (3H, s, OCH3), 4.25 (1H, br s, α-CH Val), 4.43-
4.45 (1H, m, α-CH Pro), 4.65-4.67 (1H, m, α-CH Ala), 4.69-4.71 (1H, m, α-CH Ala), 
5.21 (1H, d, J 7.6 Hz, NH), 7.30 (1H, br s, NH), 8.12 (3H, s, NH3
+
).  
 
Synthesis of Fmoc-Ala-Ala-Pro-Val-OMcm 3a. The peptide Fmoc-Ala-Ala-Pro-Val-
OH 2a (0.135 g, 0.23 mmol, 1 equiv) was added to a solution of 4-chloromethyl-7-
methoxycoumarin 1a (0.079 g, 0.35 mmol, 1.5 equiv) and potassium fluoride (0.041 g, 
0.70 mmol, 3 equiv) in dry DMF (3 mL). The mixture was stirred at room temperature 
for 48 h. The solid was filtered and the solvent was evaporated to dryness. The 
coumarin labelled peptide 3a was obtained as a light orange solid (0.174 g, 97%). 
1
H 
NMR (CDCl3, 400 MHz): δ 0.86-0.90 (6H, m, 2 × -CH3 Val), 1.36-1.38 (6H, m, 2 × 
CH3 Ala), 1.94-2.01 (2H, m, H-4 Pro), 2.09-2.12 (2H, m, H-3 Pro), 2.19-2.22 (1H, m, β-
CH Val), 3.65-3.72 (2H, m, H-5 Pro), 3.85 (3H, s, OCH3), 4.32-4.38 (1H, m, α-CH 
Ala), 4.45 (1H, t, J 6.8 Hz, H-9 Fmoc), 4.47-4.51 (1H, m, α-CH Val), 4.63-4.67 (1H, m, 
α-CH Pro), 4.68-4-70 (3H, m, α-CH Ala and CH2 Fmoc), 5.23 (2H, d, J 1.6 Hz, CH2 
Mcm), 6.38 (1H, s, H-3 Mcm), 6.78-6.82 (2H, m, H-6 and H-8 Mcm), 7.28 (3H, t, J 7.2 
Hz, H-2 and H-7 Fmoc and NH), 7.35 (3H, t, J 7.2 Hz, H-3 and H-6 Fmoc and NH), 
7.42 (1H, d, J 7.2 Hz, H-5 Mcm), 7.67 (2H, d, J 7.2 Hz, H-4 and H-5 Fmoc), 7.71 (2H, 
d, J 7.6 Hz, H-1 and H-8 Fmoc), 7.61 (1H, br s, NH). 
 
Synthesis of Fmoc-Ala-Ala-Pro-Val-OPym 3b. The peptide Fmoc-Ala-Ala-Pro-Val-
OH 2a (0.135 g, 0.23 mmol, 1 equiv) was added to a solution of 1-chloromethylpyrene 
1b (0.088 g, 0.35 mmol, 1.5 equiv) and potassium fluoride (0.041 g, 0.70 mmol, 3 
equiv) in dry DMF (3 mL). The mixture was stirred at room temperature for 48 hours. 
The solid was filtered and the solvent was evaporated to dryness. The crude solid was 
purified by silica gel column chromatography using ethyl acetate/petroleum ether (4:6) 
as eluent. The fractions containing the product were combined and evaporated to 
dryness and the pyrene-labelled peptide 3b was obtained as a beige solid (0.118 g, 
65%). 
1
H NMR (CDCl3, 400 MHz): δ 0.78-0.83 (6H, m, 2 × -CH3 Val), 1.33-1.35 (6H, 
m, 2 × CH3 Ala), 1.90-2.14 (4H, m, H-4 Pro and H-3 Pro), 2.33 (1H, m, β-CH Val), 
3.48-3.55 (2H, m, H-5 Pro), 4.53-4.60 (3H, m, α-CH Val, α-CH Ala and H-9 
Fmoc),4.64-4.71 (4H, m, α-CH Pro, α-CH Ala and CH2 Fmoc), 5.79 (2H, d, J 6.8 Hz, 
CH2 Pym), 7.27-7.38 (4H, m, H-2, H-3, H-6 and H-7 Fmoc), 7.68-7.75 (4H, m, H-1, H-
4, H-5 and H-8 Fmoc), 7.82 (1H, d, J 6.8 Hz, NH), 8.01-8.18 (11H, m, 9 × H-Pym and 
2 × NH).  
 
Synthesis of H-Ala-Ala-Pro-Val-OMcm 4a. The peptide Fmoc-Ala-Ala-Pro-Val-
OMcm 3a (0.170 g, 0.22 mmol) was treated with a solution of 20% piperidine in DMF 
(5 mL), stirring at room temperature for 3 hours. The mixture was concentrated by 
evaporation under vacuum without heating and treated with diethyl ether to precipitate 
the resulting peptide 4a as a light yellow solid (0.050 g, 41%). Mp = 256.5-258.0 ºC. 
1
H 
NMR (CDCl3, 400 MHz): δ 0.95-1.02 (6H, m, 2 × -CH3 Val), 1.37-1.41 (6H, m, 2 × 
CH3 Ala), 1.88-1.93 (2H, m, H-4 Pro), 1.96-1.99 (2H, m, H-3 Pro), 2.17-2.23 (1H, m, β-
CH Val), 3.78-3.79 (3H, m, H-5 Pro and α-CH Ala), 3.90 (3H, s, OCH3), 4.17 (1H, br d, 
J 4.4 Hz, α-CH Val), 4.55-4.57 (1H, m, α-CH Pro), 4.62-4.64 (1H, m, α-CH Ala), 5.42 
(2H, s, CH2 Mcm), 6.36 (1H, s, H-3 Mcm), 6.92-6.97 (1H, m, H-6 and H-8 Mcm), 7.62 
(1H, d, J 7.2 Hz, H-5 Mcm) (NH protons not visible). 
13
C NMR (CDCl3, 100.6 MHz): δ 
18.37 (CH3 Ala), 18.64 (CH3 Ala), 19.57 (-CH3 Val), 20.19 (-CH3 Val), 23.09 (C-3 
Pro), 23.76 (C-4 Pro), 31.59 (β-CH Val), 45.71 (C-5 Pro), 56.39 (OCH3), 56.48 (α-CH 
Ala), 59.60 (α-CH Val), 61.04 (α-CH Pro), 61.76 (α-CH Ala), 63.02 (CH2 Mcm), 
102.05 (C-8 Mcm), 108.62 (C-4a Mcm), 110.78 (C-3 Mcm), 111.83 (C-6 Mcm), 113.84 
(C-5 Mcm), 156.77 (C-4 Mcm), 158.19 (C-8a Mcm), 162.88 (C-2 Mcm), 164.70 (C-7 
Mcm), 172.29 (C=O Pro), 173.22 (C=O Ala), 173.53 (C=O Ala), 174.57 (C=O Val). 
HRMS (ESI): calcd for C27H37N4O8 [M
+
+H]: 545.26131; found: 545.26174. 
 
Synthesis of Ala-Ala-Pro-Val-OPym 4b. The peptide Fmoc-Ala-Ala-Pro-Val-OPym 
3b (0.110 g, 0.14 mmol) was treated with a solution of 20% piperidine in DMF (5 mL), 
stirring at room temperature for 3 hours. The mixture was concentrated by evaporation 
under vacuum without heating and treated with diethyl ether to precipitate the resulting 
peptide 4b as a light yellow oil (0.050 g, 63%). 
1
H NMR (CDCl3, 400 MHz): δ 0.87-
0.92 (6H, m, 2 × -CH3 Val), 1.31-1.34 (6H, m, 2 × CH3 Ala), 1.58-1.63 (2H, m, H-4 
Pro), 1.82-1.87 (2H, m, H-3 Pro), 2.12-2.17 (1H, m, β-CH Val), 3.45-3.55 (2H, m, H-5 
Pro), 3.58-3.60 (1H, m, α-CH Ala), 4.32-4.33 (1H, m, α-CH Val), 4.38-4.41 (1H, m, α-
CH Pro), 4.54-4.56 (1H, m, α-CH Ala), 5.77 (2H, d, J 4.8 Hz, CH2 Pym), 8.04-8.22 
(11H, m, 9 × H-Pym and 2 × NH) (NH2 protons not visible). 
13
C NMR (CDCl3, 100.6 
MHz): δ 16.88 (CH3 Ala), 18.52 (-CH3 Val), 19.47 (-CH3 Val), 19.91 (CH3 Ala), 
25.65 (C-4 Pro), 30.02 (C-3 Pro), 31.59 (β-CH Val), 45.74 (C-5 Pro), 50.81 (α-CH Ala), 
59.66 (α-CH Ala), 60.87 (α-CH Pro and α-CH Val), 66.16 (CH2 Pym), 128.17 (C-Pym), 
128.34 (C-Pym), 128.38 (C-Pym), 128.76 (C-Pym), 128.80 (C-Pym), 128.96 (C-Pym), 
129.10 (C-Pym), 129.23 (C-Pym), 129.33 (C-Pym), 129.37 (C-Pym), 129.85 (C-Pym), 
130.00 (C-Pym), 130.85 (C-Pym), 132.03 (C-Pym), 132.55 (C-Pym), 133.23 (C-Pym), 
172.75 (C=O Val), 173.12 (C=O Ala), 174.38 (C=O Pro), 175.33 (C=O Ala). HRMS 
(ESI): calcd for C33H39N4O5 [M
+
+H]: 571.29227; found: 571.29193. 
 
Synthesis of Boc-Ala-Ala-Pro-Val-OMcm 4c. The peptide Boc-Ala-Ala-Pro-Val-OH 
2c (0.105 g, 0.23 mmol, 1 equiv) was added to a solution of 4-chloromethyl-7-
methoxycoumarin 1a (0.079 g, 0.35 mmol, 1.5 equiv) and potassium fluoride (0.041 g, 
0.70 mmol, 3 equiv) in dry DMF (3 mL). The mixture was stirred at room temperature 
for 48 hours. The solid was filtered and the solvent was evaporated to dryness. The 
crude solid was purified by silica gel column chromatography using DCM/MeOH 
(50:1) as eluent. The fractions were combined and evaporated and the coumarin labelled 
peptide 4c was obtained as a light yellow solid (0.101 g, 83%). Mp = 137.9 – 138.3 ºC. 
1
H NMR (CDCl3, 400 MHz): δ 0.90-0.94 (6H, m, 2 × -CH3 Val), 1.34-1.39 (6H, m, 2 
× CH3 Ala), 1.44 (9H, s, C(CH3)3), 1.99-2.10 (2H, m, H-4 Pro), 2.15-2.21 (1H, m, β-CH 
Val), 2.40-2.45 (1H, m, H-3 Pro), 3.51-3.66 (2H, m, H-5 Pro), 3.89 (3H, s, OCH3), 4.28 
(1H, br s, α-CH Ala), 4.56-4.59 (1H, m, α-CH Pro), 4.69-4.72 (2H, m, α-CH Val), 4.77-
4.81 (1H, m, α-CH Ala), 5.19 (1H, br s, NH), 5.30-5.36 (2H, m, CH2 Mcm), 6.58 (1H, s, 
H-3 Mcm), 6.86-6.90 (2H, m, H-6 and H-8 Mcm), 7.41 (2H, d, J 8.4 and 6.8 Hz, H-5 
Mcm and NH), 7.67 (1H, d, J 8.0 Hz, NH). 
13
C NMR (CDCl3, 100.6 MHz): δ 17.71 
(CH3 Ala), 18.58 (-CH3 Val), 18.89 (CH3 Ala), 19.09 (-CH3 Val), 25.14 (C-4 Pro), 
26.58 (C-3 Pro), 28.32 (C(CH3)3), 31.18 (β-CH Val), 46.65 (α-CH Ala), 47.40 (C-5 
Pro), 50.06 (α-CH Ala), 55.82 (OCH3), 57.74 (α-CH Pro), 59.84 (α-CH Val), 61.86 
(CH2 Mcm), 79.90 (C(CH3)3), 101.29 (C-8 Mcm), 110.34 (C-3 Mcm), 110.48 (C-4a 
Mcm), 112.74 (C-6 Mcm), 124.37 (C-5 Mcm), 148.53 (C-4 Mcm), 154.86 (C8a Mcm), 
155.53 (C=O Boc), 161.04 (C- 2 Mcm), 162.95 (C-7 Mcm), 170.56 (C=O Val), 170.81 
(C=O Pro), 172.26 (C=O Ala), 172.94 (C=O Ala). HRMS (ESI): calcd for C32H45N4O10 
[M
+
+H]: 645.31375; found: 645.31351. 
 
Synthesis of Poc-Ala-Ala-Pro-Val-OMe 4d. N’,N’-Carbonyldiimidazole (0.061 g; 
0.38 mmol, 1 equiv) was dissolved in dry DMF (2 mL) in an ice bath, then 1-pyrene 
methanol 1c (0.087 g; 0.38 mmol, 1 equiv) was added slowly and the solution was left 
stirring for 1 hour at low temperature. The peptide H-Ala-Ala-Pro-Val-OMe 2d in the 
form of hydrochloride (0.182 g; 0.38 mmol, 1 equiv) was neutralised with triethylamine 
in dry DMF (2 mL). The triethylammonium chloride was filtered and the solution was 
added to the previous mixture and left stirring at room temperature for 12 hours. The 
solvent was evaporated to dryness and the crude residue was purified by silica gel 
column chromatography using ethyl acetate/petroleum ether (4:6) as eluent. The 
fractions containing the product were combined and evaporated to yield the pyrene-
labelled peptide 4d as an off-white solid (0.024 g, 10%). 
1
H NMR (CDCl3, 400 MHz): δ 
0.87-0.88 (6H, m, 2 × -CH3 Val), 1.15-1.18 (6H, m, 2 × CH3 Ala), 1.87-1.89 (2H, m, 
H-4 Pro), 1.92-1.98 (1H, m, β-CH Val), 1.99-2.01 (2H, m, H-3 Pro), 3.38-3.41 (2H, m, 
H-5 Pro), 3.78 (3H, s, OCH3), 4.25-4.26 (1H, m, α-CH Ala), 4.27-4.28 (1H, m, α-CH 
Val), 4.30-4.31 (1H, m, α-CH Pro), 4.33-4.35 (1H, m, α-CH Ala), 5.23 (1H, br s, NH),  
5.74 (2H, d, CH2 Pym), 7.93-8.15 (11H, m, 9 × H-Pym and 2 × NH). 
13
C NMR (CDCl3, 
100.6 MHz): δ 16.90 (CH3 Ala), 18.51 (-CH3 Val), 19.45 (-CH3 Val), 19.92 (CH3 
Ala), 25.68 (C-4 Pro), 30.07 (C-3 Pro), 31.60 (β-CH Val), 45.75 (C-5 Pro), 50.85 (α-CH 
Ala), 52.51 (OCH3), 59.75 (α-CH Ala), 60.78 (α-CH Pro), 60.82 (α-CH Val), 61.76 
(CH2 Poc), 128.19 (C-Poc), 128.37 (C-Poc), 128.41 (C-Poc), 128.72 (C-Poc), 128.75 
(C-Poc), 128.94 (C-Poc), 129.13 (C-Poc), 129.24 (C-Poc), 129.38 (C- Poc), 129.45 (C-
Poc), 129.81 (C-Poc), 130.04 (C-Poc), 130.80 (C-Poc), 132.05 (C-Poc), 132.59 (C-
Poc), 133.21 (C-Poc), 155.62 (C=O Poc), 172.77 (C=O Val), 173.22 (C=O Ala), 174.44 
(C=O Pro), 175.36 (C=O Ala). HRMS (ESI): calcd for C35H41N4O7 [M
+
+H]: 
629.29773; found: 629.29810. 
 
Photolysis general procedure 
A 1  10-4 M MeOH/HEPES (80:20) or ACN/HEPES (80:20) solution of compounds 
4a-d (5 mL) were placed in a quartz tube and irradiated in a Rayonet RPR-100 reactor 
at the desired wavelength. The lamps used for irradiation were of 254, 300, and 350 ± 
10 nm. HEPES buffer solution was prepared in distilled water with HEPES (4-(2-
hydroxyethyl)-1-piperazine ethanesulfonic acid) (10 mM), sodium chloride (120 mM), 
potassium chloride (3 mM), calcium chloride (1 mM) and magnesium chloride (1mM) 
and pH adjusted to 7.2 with aqueous 1 M sodium hydroxide solution. Aliquots of 100 
µL were taken at regular intervals and analysed by RP-HPLC using a Licrospher 100 
RP18 (5 μm) column in a JASCO HPLC system composed by a PU-2080 pump and a 
UV-2070 detector with ChromNav software. The eluent was ACN/water (3:1) at a flow 
rate of 0.8 mL/min for compounds 4c-d, or ACN/water (3:1) with 0.1% TFA at a flow 
rate of 0.6 mL/min for compounds 4a-b, previously filtered through a Millipore, type 
HN 0.45 µm filter and degassed by ultra-sound for 30 min. The chromatograms were 
traced by detecting UV absorption at the wavelength of maximum absorption for each 
compound at the corresponding solvent (retention time in minutes: 4a, 15.5; 4b, 17.2; 
4c, 6.9; 4d, 8.5).  
Results and discussion 
Synthesis of caged AAPV derivatives 4a-d 
Coumarin and pyrene derivatives 1a-c were chosen as photosensitive groups to assess 
their influence in the uncaging of the model bioactive tetrapeptide Ala-Ala-Pro-Val 
(AAPV), by introducing these groups at the N- and C-terminals of the peptide through 
carbamate or ester linkages, respectively. 
4-Chloromethyl-7-methoxycoumarin 1a was obtained by a Pechmann reaction between 
3-methoxyphenol and ethyl 4-chloro-3-oxobutanoate, catalysed by acid, in 93% yield, 
by a previously published procedure (Piloto et al. 2006). This heterocycle has been used 
previously by us as caging group for amino acids with interesting photosensitivity 
(Fonseca et al. 2007; Fonseca et al. 2010). Likewise, pyrene-based photolabile groups 
were also applied by us in the caging of neurotransmitter amino acids and biogenic 
amines (Fernandes et al. 2007; Fernandes et al. 2008; Fernandes et al. 2013). So, 4-
chloromethyl-7-methoxycoumarin 1a, 1-choloromethylpyrene 1b and 1-
pyrenemethanol 1c were used in the derivatization of AAPV at the C- and N-terminals. 
The synthesis of Fmoc-AAPV-OH 2a was accomplished by a solid phase synthesis 
protocol in an acid-labile 2-chlorotritylchloride resin on a manual microwave-assisted 
peptide synthesizer (CEM Discover) (Scheme 1). The resin and the necessary Fmoc-
amino acids were commercially available and the resin had a functionalisation degree of 
0.84 mmol/g. Amino acid coupling reactions were carried out in dry DMF in the 
presence of N,N’-diisopropylcarbodiimide (DIC) and 6-chloro-N-hydroxybenzotriazole 
(6-Cl-HOBt) (a 5 equiv excess was used), with a standard MW coupling protocol (5 
minutes, 28 W, 75°C). After each coupling, the Fmoc protecting group was removed 
with 20% piperidine in DMF solution using a standard MW protocol (30 seconds cycle 
plus a 3 minutes’ cycle, 28 W, 75 oC). The cleavage of the peptide 2a from the resin 
was achieved by treatment with a AcOH/TFE/DCM (1:1:3) cocktail and Fmoc-AAPV-
OH 2a was isolated as a solid in 85% yield. The purity was checked by analytical 
HPLC and the peptide was characterised by 
1
H and 
13
C NMR spectroscopy and high-
resolution mass spectrometry. 
After removal of the Fmoc group from peptide 2a to give free H-AAPV-OH 2b (in 90% 
yield), reaction with t-butyl pyrocarbonate afforded Boc-AAPV-OH 2c in 82% yield, 
while reaction with methanol and thionyl chloride resulted in the respective methyl ester 
H-AAPV-OMe 2d in the form of hydrochloride salt in quantitative yield (Scheme 1).  
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Scheme 1. Synthesis of AAPV derivatives 2a-d by MW-SPPS on a 2-chlorotrityl 
chloride resin. Reaction conditions: i) 20% piperidine in DMF, rt; ii) Boc2O, aq. 1M 
NaOH  1,4-dioxane, rt ; iii) SOCl2, MeOH, rt. 
 
The chloromethyl precursors 1a,b were reacted with Fmoc-AAPV-OH 2a in the 
presence of potassium fluoride in DMF (Tjoeng and Heavner 1981)
 
to afford the 
corresponding ester conjugate peptides Fmoc-AAPV-OMcm 3a (97%) and Fmoc-
AAPV-OPym 3b (65%) (Mcm will be used to designate the methoxycoumarinylmethyl 
group whereas Pym will represent the pyrenylmethyl group) (Scheme 2, Table 1). 
Considering the aromatic nature of the Fmoc protecting group, which could interfere 
with the photocleavage process by competitive radiation absorption, it was decided to 
remove this group prior to subjecting the peptides to irradiation. Therefore, treatment 
with 20% piperidine in DMF solution afforded the N-deprotected peptides H-AAPV-
OMcm 4a (in 41% yield) and H-AAPV-OPym 4b (in 63% yield). 
In a similar manner, chloromethylated coumarin 1a was reacted with Boc-AAPV-OH 
2c in the presence of potassium fluoride in DMF,
 
resulting in Boc-AAPV-OMcm 4c in 
83% yield. As for peptide Poc-AAPV-OMe 4d, it was obtained by reaction of AAPV-
OMe 2d with 1-pyrenemethanol 1c mediated by N’,N’-carbonyldiimidazole (CDI). The 
product was isolated after column chromatography in lower yield (10%) (Poc will be 
used to designate the pyrenylmethoxycarbonyl group). The purity of the C-and N-
terminal caged peptides 4a-d was checked by analytical HPLC and the peptides were 
characterised by 
1
H and 
13
C NMR spectroscopy and high-resolution mass spectrometry. 
1
H NMR spectra showed the characteristic signals of the photosensitive groups in the 
aromatic zone and the methylene group, adjacent to the ester or carbamate link, was 
visible between δ 5.30-5.77 ppm. The newly formed ester or carbamate linkages in 
caged peptide 4a-d were confirmed by 
13
C NMR spectra signals of the carbonyl group, 
at about δ 170.56-174.57 (for the esters) or δ 155.62 ppm (for the carbamate). 
 
 
Scheme 2. Synthesis of caged AAPV derivatives 4a-d. Reaction conditions: i) KF, 
DMF, rt; ii) 20% piperidine in DMF, rt; iii) CDI, DMF, rt. 
 
Photophysical characterisation of caged peptides 4a-d 
Given the highly conjugated structure of the photosensitive groups, coumarin and 
pyrene, which are known for displaying strong absorption and fluorescence in the 
UV/vis, fundamental UV/vis absorption characterisation was performed for the caged 
peptides 4a-d, also considering that their photolysis would be monitored by HPLC with 
UV detection. For the photolysis studies, it was decided to evaluate the influence of a 
protic (methanol) and aprotic (acetonitrile) solvent on the photolysis rates. 
The absorption spectra of degassed 10
-4
 M solutions in MeOH/HEPES buffer (80:20) 
and ACN/HEPES buffer (80:20) solutions of caged peptides 4a-d were measured and 
the absorption maxima (λmax), and molar absorption coefficients (log ε) are reported in 
Table 1.  
 
Table 1. UV/vis absorption data for caged peptides 4a-d in MeOH/HEPES buffer 
(80:20) and ACN/HEPES buffer (80:20) solutions. 
Compound 
UV/vis absorption 
MeOH/HEPES (80:20) ACN/HEPES (80:20) 
λmax (nm) log ε λmax  (nm) log ε 
H-AAPV-OMcm 
4a 
325 3.89 323 3.84 
H-AAPV-OPym 
4b 
342 4.39 342 4.43 
Boc-AAPV-OMcm 
4c 
325 4.29 320 4.07 
Poc-AAPV-OMe 
4d 
342 4.38 341 4.30 
 
From the data in Table 1, it can be seen that the nature of the organic solvent did not 
influence significantly the absorption maxima: the values were very similar in both 
solvents, with the exception of peptide 4c, for which a bathochromic shift of 5 nm was 
observed when comparing the protic and the aprotic solvent. As for the nature of the 
photosensitive group, the presence of the pyrene group led to larger λmax (between 17-19 
nm) in both solvents for peptides 4a (bearing a C-terminal coumarin) and 4b (bearing a 
a C-terminal pyrene). 
 
Considering the fluorescent nature of the photosensitive groups, the fluorescence of 
caged peptide 4c, as representative example, was studied in different organic solvents 
and aqueous mixtures. Emission maxima (λem) and relative fluorescence quantum yields 
(ΦF) are given in Table 2. Relative fluorescence quantum yields were calculated using 
9,10-diphenylanthracene in ethanol (F 0.95) (Morris et al. 1976) as standard. For the 
ΦF determination, the fluorescence standard was excited at the maximum absorption 
wavelength, in each solvent, and in all fluorimetric measurements the absorbance of the 
solution did not exceed 0.1. The fluorescence displayed by the caged peptides 4a-d is an 
interesting feature since it allows the monitoring of the processes and dynamics in 
which these peptides could participate by fluorescence spectroscopy. 
 
Table 2. UV/vis absorption and fluorescence data for caged peptide Boc-AAPV-OMe 
4c in different organic solvents and aqueous mixtures. 
Solvent 
UV/vis absorption  Fluorescence  
λmax (nm) log ε λem  (nm) ΦF 
Stokes’ shift 
(nm) 
EtOH 325 4.05 394 0.34 69 
MeOH 319 4.11 399 0.58 80 
ACN 319 4.24 393 0.12 74 
MeOH/HEPES (80:20) 325 4.29 400 0.76 75 
ACN/HEPES (80:20) 320 3.54 397 0.56 77 
 
The collected data revealed similar wavelengths of maximum absorption and emission, 
but the relative fluorescence quantum yield varied significantly being higher in protic 
solvents/mixtures (Table 2). The overall trend revealed that caged peptide 4c was more 
fluorescent in aqueous mixtures, especially with methanol. This fact is of great 
significance for future biological applications involving fluorescence based techniques, 
as it could maximize the response and, consequently, increase the sensitivity of 
detection of the labelled peptide in aqueous media (Figure 1). The Stokes’ shifts varied 
between 69-80 nm and a large Stokes’ shift is an attractive characteristic for a 
fluorescent probe in biological media that allows an improved separation of the light 
inherent to the matrix and the light dispersed by the sample.  
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Figure 1. Normalised fluorescence spectra of caged peptide 4c in different solvents (C 
= 7.6  10-6 M). 
 
Photolysis studies of caged peptides 4a-d 
Evaluation of the 7-methoxycoumarinylmethyl and pyrenylmethyl groups as 
photosensitive units for the caging of peptides, using AAPV as a model bioactive 
tetrapeptide, was carried out. Accordingly, peptides 4a-d were irradiated at 254 nm, 300 
nm and 350 nm in mixtures of methanol or acetonitrile with aqueous HEPES buffer in 
80:20 solutions, in a Rayonet RPR-100 reactor, and kinetic data were collected. The 
course of the photolytic reaction was followed by reverse phase HPLC with UV 
detection and the disappearance of the peptide conjugates and the release of the 
corresponding peptide precursors was monitored (Scheme 3). The plots of peak area (A) 
of the starting material versus irradiation time were obtained for each compound, at 
chosen wavelengths. The peak areas were determined by HPLC, which revealed a 
gradual decrease with time and were taken as the average of three runs. The irradiation 
time (tirr) given represents the time necessary for the consumption of the starting 
materials until less than 5% of the initial area was detected (Table 3). The 
photochemical quantum yields (ΦPhot) were calculated based on half-lives (t1/2), molar 
extinction coefficients () and the incident photon flux (I0), which was determined by 
potassium ferrioxalate actinometry (Muller et al. 2001). The rate constants (k) were 
calculated for a short conversion (30%) of the initial conjugates. 
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Scheme 3. Photolysis of caged peptides 4a-d by irradiation at 254, 300, and 350 nm in 
MeOH/HEPES buffer (80:20) and ACN/HEPES buffer (80:20) solutions. 
 
Table 3. Irradiation times (tirr in min), photochemical quantum yields (Φphot,  10
-3
) and 
rate contants (k, in min
-1
) for the photolysis of caged peptides 4a-d by irradiation at 254, 
300, and 350 nm in MeOH/HEPES buffer (80:20) and ACN/HEPES buffer (80:20) 
solutions. 
Cpd. 
Solvent
a)
 
254 nm 300 nm 350 nm 
tirr Φphot k tirr Φphot k tirr Φphot k 
4a 
A 40 0.335 0.083 41 0.019 0.114 352 0.018 0.009 
B 46 0.400 0.106 55 0.148 0.081 1108 0.007 0.006 
4b 
A 18 0.162 0.113 32 0.075 0.129 310 0.006 0.006 
B 81 0.056 0.068 53 0.042 0.115 389 0.004 0.003 
4c 
A 57 0.087 0.076 347 0.012 0.025 2080 0.001 0.002 
B 74 0.125 0.040 163 0.038 0.017 2169 0.002 0.001 
4d 
A 4.4 1.050 0.806 8.3 0.274 0.404 46 0.045 0.073 
B 
b) b) b) b) b) b) 
162 0.013 0.018 
a)
 A = MeOH/HEPES (80:20); B = ACN/HEPES (80:20). 
b) 
Not determined. 
 
The data in Table 3 revealed that, by irradiation at 254 nm, the time necessary for the 
release of the bioactive peptide from cages 4a-c was larger in ACN/HEPES, with this 
difference being more accentuated for caged peptide 4b. For peptides 4a and 4c, the 
presence of a N-butyloxycarbonyl protecting group resulted in a slightly longer 
irradiation time for the N-protected peptide (4c). When considering the different 
photosensitive groups linked through an ester bond at this wavelength of irradiation, 
there was no clear tendency in the irradiation times in the solvents tested: the 
pyrenylmethyl group (Pym) cleaved faster in MeOH/HEPES while the 
coumarinylmethyl group (Mcm) cleaved faster in ACN/HEPES. In terms of the 
influence of the type of linkage between the photosensitive group and the peptide, in the 
case of pyrene it was observed that a carbamate link, as in Poc-AAPV-OMe 4d, cleaved 
much faster (ca. 4 times) that the corresponding counterpart with an ester link, as in H-
AAPV-OPym 4b. Irradiation at 300 nm afforded similar observations: once again the 
carbamate caged peptide 4d was the fastest to cleave and the influence of the presence 
of a N-Boc led to a dramatic difference in irradiation times, which occurred in peptide 
4c (Boc-AAPV-OMcm), in comparison with and 4a (H-AAPV-OMcm).  
At 350 nm, the influence of the solvent was clear with photolysis being faster in 
MeOH/HEPES for all caged peptides. At this wavelength of irradiation, the obtained 
irradiation times were too large to be of practical use, except for carbamate caged 
peptide Pym-AAPV-OMe 4d in MeOH/HEPES, which cleaved readily in ca. 46 min. 
The relationship between the molar extinction coefficient of the conjugates at the 
wavelengths of irradiation and the photolysis rate constants was confirmed, as larger 
rate constants were obtained when the molar extinction coefficient was also larger, 
which was expected due to the higher probability of absorbing radiation and undergoing 
a photolytic pathway. For compound 4c, nevertheless, this trend was not followed at 
350 nm irradiation, which may be related to its tendency to undergo a radiative pathway 
(as seen by the high relative fluorescence quantum yields in the studied solvent 
mixtures). 
Overall, in the photolysis studies the time necessary to release the active peptide was 
shorter when photolyses were carried out in the more polar and protic solvent, 
MeOH/HEPES (80:20) and when the photosensitive group was linked to the peptide by 
a carbamate bond, as in peptide 4d. Given the need to minimise cellular damage in the 
uncaging of molecules with biological activity by using wavelengths longer than 350 
nm, the most suitable for biological applications, only the data obtained by irradiation at 
350 nm for peptide 4d constitute a promising result for future development. 
Nevertheless, the reported results reflect the uniqueness of the experimental setup and 
this work intends to be a preliminary assessment of the applicability of the tested 
photoactive groups in the photorelease of AAPV. As a follow-up of this work, the most 
promising AAPV cage 4d will undergo a more detailed study using time-resolved 
fluorescence spectroscopy to characterise its photophysical properties. This kind of 
studies have been previously reported by us, regarding other bioactive targets, in order 
to relate to the conjugate, the ion pair intermediate and photocleaved species, by the 
determination of decay associated spectra to enable both spectral (energetic) and decay 
kinetics to be compared. 
 
For each peptide, based on HPLC data, the plot of ln A versus irradiation time showed a 
linear correlation for the disappearance of the starting caged peptide. Although this 
fitting suggests a first order reaction, obtained by the linear least squares methodology 
for a straight line (Figure 2), one should not consider the behaviour of this system 
unequivocally as such, since deviations may occur considering that after photocleavage 
there are several absorbing species in solution (the caged peptide, the released 
photoactive moiety and the peptide). 
 
10,0
11,0
12,0
13,0
14,0
15,0
0 5 10 15 20 25 30
ln
 A
Irradiation time (min)
254 nm 4 b (MeOH/HEPES)
4 b (ACN/HEPES)
4 a (MeOH/HEPES)
4 a (ACN/HEPES)
4 d (MeOH/HEPES)
4 c (MeOH/HEPES)
4 c (ACN/HEPES)
 
11,0
12,0
13,0
14,0
15,0
0 10 20 30 40 50 60 70 80 90 100
ln
 A
Irradiation time (min)
300 nm 4 b (MeOH/HEPES)
4 b (ACN/HEPES)
4 a (MeOH/HEPES)
4 a (ACN/HEPES)
4 d (MeOH/HEPES)
4 c (MeOH/HEPES)
4 c (ACN/HEPES)
 
9,0
10,0
11,0
12,0
13,0
14,0
15,0
0 50 100 150 200 250 300 350
ln
 A
Irradiation time (min)    
350 nm
4 b (MeOH/HEPES)
4 b (ACN/HEPES)
4 a (MeOH/HEPES)
4 a (ACN/HEPES)
4 d (MeOH/HEPES)
4 d (ACN/HEPES)
4 c (MeOH/HEPES)
4 c (ACN/HEPES)
 
 
Figure 2. Plot of ln A vs irradiation time for the photolysis of caged peptides 4a-d at the 
various wavelengths of irradiation in MeOH/HEPES buffer (80:20) and ACN/HEPES 
(80:20) solution. 
 
Conclusions 
Two photosensitive groups based on coumarin and pyrene were used for the first time in 
the preparation of ester and carbamate cages of Ala-Ala-Pro-Val (AAPV), a bioactive 
tetrapeptide that inhibits human neutrophil elastase (HNE), an enzyme involved in 
chronic inflammatory disease of the skin. Caged AAPV was subjected to photolysis at 
selected wavelengths (254, 300, and 350 nm), to assess the feasibility and influence of 
the photosensitive group and the type of linkage in the controlled photorelease of the 
active molecule, which was monitored by HPLC-UV. 
The obtained data confirmed the applicability of the tested photoactive groups for the 
release of AAPV, especially for the derivative bearing the carbamate-linked 
pyrenylmethyl group, which displayed the shortest irradiation times for the release at 
the various wavelengths of irradiation (ca. 4 minutes at 254 nm, 8 minutes at 300 nm 
and 46 minutes at 350 nm). 
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CAPTIONS 
 
 
Table 1. UV/vis absorption data for caged peptides 4a-d in MeOH/HEPES buffer 
(80:20) and ACN/HEPES buffer (80:20) solutions. 
  
Table 2. UV/vis absorption and fluorescence data for caged peptide Boc-AAPV-OMcm 
4c in different organic solvents and aqueous mixtures. 
 
Table 3. Irradiation times (tirr in min), photochemical quantum yields (Φphot,  10
-3
) and 
rate contants (k, in min
-1
) for the photolysis of caged peptides 4a-d by irradiation at 254, 
300, and 350 nm in MeOH/HEPES buffer (80:20) and ACN/HEPES buffer (80:20) 
solutions. 
a)
 A = MeOH/HEPES (80:20); B = ACN/HEPES (80:20). 
b) 
Not determined. 
 
Scheme 1. Synthesis of AAPV derivatives 2a-d by MW-SPPS on a 2-chlorotrityl 
chloride resin. Reaction conditions: i) 20% piperidine in DMF, rt; ii) Boc2O, aq. 1M 
NaOH  1,4-dioxane, rt ; iii) SOCl2, MeOH, rt. 
 
Scheme 2. Synthesis of caged AAPV derivatives 4a-d. Reaction conditions: i) KF, 
DMF, rt; ii) 20% piperidine in DMF, rt; iii) CDI, DMF, rt. 
 
Scheme 3. Photolysis of caged peptides 4a-d by irradiation at 254, 300, and 350 nm in 
MeOH/HEPES buffer (80:20) and ACN/HEPES buffer (80:20) solutions. 
 
Figure 1. Normalised fluorescence spectra of caged peptide 4c in different solvents (C 
= 7.6  10-6 M). 
 
Figure 2. Plot of ln A vs irradiation time for the photolysis of caged peptides 4a-d at the 
various wavelengths of irradiation in MeOH/HEPES buffer (80:20) and ACN/HEPES 
(80:20) solution. 
 
TABLES 
 
 
Table 1.  
 
Compound 
UV/vis absorption 
MeOH/HEPES (80:20) ACN/HEPES (80:20) 
λmax (nm) log ε λmax  (nm) log ε 
H-AAPV-OMcm 
4a 
325 3.89 323 3.84 
H-AAPV-OPym 
4b 
342 4.39 342 4.43 
Boc-AAPV-OMcm 
4c 
325 4.29 320 4.07 
Poc-AAPV-OMe 
4d 
342 4.38 341 4.30 
 
 
 
Table 2. 
 
Solvent 
UV/vis absorption  Fluorescence  
λmax (nm) log ε λem  (nm) ΦF 
Stokes’ shift 
(nm) 
EtOH 325 4.05 394 0.34 69 
MeOH 319 4.11 399 0.58 80 
ACN 319 4.24 393 0.12 74 
MeOH/HEPES (80:20) 325 4.29 400 0.76 75 
ACN/HEPES (80:20) 320 3.54 397 0.56 77 
 
 
 
 
Table 3.  
 
 
Cpd. 
Solvent
a)
 
254 nm 300 nm 350 nm 
tirr Φphot k tirr Φphot k tirr Φphot k 
4a 
A 40 0.335 0.083 41 0.019 0.114 352 0.018 0.009 
B 46 0.400 0.106 55 0.148 0.081 1108 0.007 0.006 
4b 
A 18 0.162 0.113 32 0.075 0.129 310 0.006 0.006 
B 81 0.056 0.068 53 0.042 0.115 389 0.004 0.003 
4c 
A 57 0.087 0.076 347 0.012 0.025 2080 0.001 0.002 
B 74 0.125 0.040 163 0.038 0.017 2169 0.002 0.001 
4d 
A 4.4 1.050 0.806 8.3 0.274 0.404 46 0.045 0.073 
B 
b) b) b) b) b) b) 
162 0.013 0.018 
 
 
 
 
SCHEMES 
 
 
Scheme 1.  
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MW (30 s + 3 min, 28 W, 75 °C)
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Scheme 3.  
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FIGURES 
 
Figure 1.  
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Figure 2.  
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